Stability of pro-gastrin-releasing peptide in serum versus plasma

Tumor Biology

Volumn 29, Issue 4, 2008, Pages 224-230

  Yoshimura, Toru ^a,c   Fujita, Kenju ^a   Kawakami, Satoshi ^a   Takeda, Katsumichi ^a   Chan, Sabrina ^b   Beligere, Gangamani ^b   Dowell, Barry ^b  

^a Abbott Japan   (Japan)

^b ABBOTT LABORATORIES   (United States)

^c Abbott Japan Co Ltd   (Japan)

Author keywords

Pro gastrin releasing peptide; Small cell lung cancer; Thrombin

Indexed keywords

BENZYLSULFONYL FLUORIDE; BIOLOGICAL MARKER; FRESH FROZEN PLASMA; PROGASTRIN RELEASING PEPTIDE; PROTHROMBIN; SERINE PROTEINASE; THROMBIN;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; LABORATORY TEST; LUNG SMALL CELL CANCER; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN STABILITY; ROOM TEMPERATURE; SERUM;

EID: 51049096389     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000152940     Document Type: Article

References (12)

1. Yamaguchi K, Abe K, Kameya T, Adachi I, Taguchi S, Otsubo K, Yanaihara N: Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res 1983;43:3932-3939.
2. Miyake M, Kodama T, Yamaguchi K: Progastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1994;54:2136-2140.
3. Aoyagi A, Miyake Y, Urakami K, Kashiwakuma T, Hasegawa A, Kodama T, Yamaguchi K: Enzyme immunoassay of immunoreactive progastrin-releasing peptide (31-98) as tumor marker for small-cell lung carcinoma: development and evaluation. Clin Chem 1995;41:537-543.
4. Yamaguchi K, Aoyagi K, Urakami K, Fukutani T, Maki N, Yamamoto S, et al: Enzymelinked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Jpn J Cancer Res 1995;86:698-705.
5. Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, Yamaguchi K: Pro-gastrin-releasing peptide (ProGRP) - a useful marker in small cell lung carcinomas. Anticancer Res 1999;19:2673-2678.
6. Shibayama T, Ueoka H, Nishi K, Kiura K, Tabata M, Miyatake K, et al: Complementary role of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 2001;32:61-69.
7. Sunaga N, Tsuchiya S, Minato K, Watanabe S, Fueki N, Hoshino H, et al: Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in smallcell lung cancer. Oncology 1999;57:143-148.
8. Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N: Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer comparison to other lung diseases. Anticancer Res 2003;23:885-894.
9. Schneider J, Philipp M, Salewski L, Velcovsky HG: Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolae (NSE) in therapy control of patients with small-cell lung cancer. Clin Lab 2003;49:35-42.
10. Kuwabara M, Shibata N, Ariyoshi Y: Lung cancer: progress in diagnosis and treatment. 1. Diagnosis and physiopathology: 4. Progress in the study of tumor markers. Nippon Naika Gakkai Zasshi 1997;86:20-26.
11. Banfi G: Stability of tumor markers CA19.9, C125, and CA15.3 in serum obtained from plain tubes and tubes containing thixotropic gel separator. Clin Chem 1997;43:2430-2431.
12. Yoshimura T, Fujita K, Kawakami S, Nagao K, Takeda K, Dowell B: Initial performance characteristics of a prototype ARCHITECT® ProGRP assay. Tumor Biology 2006;27(suppl 2):61.